Actinium Pharmaceuticals traded at $4.96 this Friday July 1st, increasing $0.15 or 3.12 percent since the previous trading session. Looking back, over the last four weeks, Actinium Pharmaceuticals gained 8.82 percent. Over the last 12 months, its price fell by 35.33 percent. Looking ahead, we forecast Actinium Pharmaceuticals to be priced at 4.97 by the end of this quarter and at 4.58 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
Daily Change

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
AbbVie 153.80 0.64 0.42% 33.54%
Amgen 245.55 2.25 0.92% -1.27%
Actinium Pharmaceuticals 4.96 0.15 3.12% -35.33%
Bioline Rx 1.30 0.02 1.56% -61.19%
Capricor Therapeutics 3.68 0.19 5.44% -26.10%
Immunogen 4.61 0.11 2.44% -28.30%
Pfizer 52.31 -0.12 -0.23% 31.66%
Seattle Genetics 180.11 3.17 1.79% 14.52%
Spectrum Pharmaceuticals 0.77 -0.01 -1.33% -78.86%

Indexes Price Day Year
US2000 1728 19.77 1.16% -25.07%

Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on Antibody Radiation-Conjugates (ARCs), which combine the targeting ability of antibodies with the cell-killing ability of radiation. Its clinical programs are focused on two primary areas: targeted conditioning prior to bone marrow transplant, adoptive cell or gene therapies and therapeutics, in combination with other therapeutic modalities. Its clinical pipeline is focused on ARCs targeting the antigens CD45 and CD33, both of which are expressed in multiple hematologic cancers. Its lead CD45-targeted conditioning product candidate, Iomab-B, via the monoclonal antibody BC8, targets CD45, an antigen expressed on leukemia and lymphoma cancer cells, B cells and stem cells. Its CD33 program is evaluating the clinical utility of Actimab-A, an ARC consisting of the anti-CD33 mAb lintuzumab linked to the potent alpha-emitting radioisotope Actinium-225 (Ac-225).